Luca Liistro
ChiomentiChiomenti houses a ‘highly seasoned’ team which stands out due to its strong corporate and commercial and public procurement expertise. Luca Liistro leads the team and utilises his ‘outstanding market insight’ to assist both domestic and overseas clients on M&A and business restructurings. Filippo Brunetti stands out due to his extensive expertise in compliance, the establishment of cooperation groups, and public health policy issues, with a strong focus on medical device and pharma product reimbursement.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Overall, very dedicated and hard-working team, offering full support and advice.'
- 'Luca Listro has a very strong healthcare practice and outstanding market insight into this sector.'
- 'The team consists of lawyers specialised in M&A and commercial contracts who all appear to be very dedicated.'
- Very high efficiency. Responsive under pressure. The team has very good business acumen.'
- 'They combine professionalism and pragmatism with an attitude that makes it a real pleasure working with them.'
- 'Highly seasoned in the health sector - deal oriented/deal maker team.'
- 'Luca Listro's responsiveness and market/sector knowledge marks him out from other lawyers carrying out M&A in this sector.'
Key clients
- Abbott S.p.A.
- Air Liquide Sanità Service
- Albis International
- Alfasigma
- Amplifon
- Artsana
- BioNTech
- BioVelocITA
- Carestream Dental Italy
- Coloplast
- Columbus Education Association
- Enterprise Therapeutics
- Fidia Farmaceutici S.p.A.
- Forest Laboratories
- Gilead Sciences
- Groupe Simago SAS
- Khiron
- Hantech
- Laboratoires Expanscience
- Menarini Group
- Moderna Inc.
- Neuraxpharm
- Recordati
- Roche S.p.A.
- Sumitomo Chemical Italia
- Surmodics
- Techwald Holding
- Viatris
- Xvivo Perfusion
- Zambon Group
- Zobele
Work highlights
- Advising Alfasigma in the acquisition of Intercept Pharmaceutical Inc., traded on the NASDAQ exchange and focused on the development of novel synthetic bile acid analogs to treat chronic liver diseases. The transaction contemplated a public tender offer and a subsequent cash merger.
- Advising Viatris on the sale of its OTC business to Cooper Consumer Health.
- Advising Novo Holdings that through a merger agreement has acquired Catalent, Inc. in a transaction that values Catalent at $16.5 billion on an enterprise value basis.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Luca Liistro